SABINA : An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries
| Autor: | Christer Janson, Santiago Quirce, Cassandra Nan, Claus Vogelmeier, Javier Nuevo, Jennifer K Quint, Andrew Menzies-Gow, Alberto Papi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
030213 general clinical medicine Respiratory Medicine and Allergy Research & Experimental Medicine THERAPY Severity of Illness Index Prescription 0302 clinical medicine Short-acting beta2-agonist MEDICATION USE Adrenal Cortex Hormones Health care Electronic Health Records Pharmacology (medical) Pharmacology & Pharmacy DRUG General Clinical Medicine Reimbursement Original Research Lungmedicin och allergi Public health Short-acting beta(2)-agonist Medical record General Medicine Middle Aged Europe Overreliance Prescription Public health Short-acting β2-agonist Europe Medicine Research & Experimental 030220 oncology & carcinogenesis Population study Drug Therapy Combination Female 1115 Pharmacology and Pharmaceutical Sciences Life Sciences & Biomedicine medicine.drug Adult medicine.medical_specialty Adolescent BETA-AGONIST USE Socio-culturale 03 medical and health sciences Young Adult BUDESONIDE-FORMOTEROL Administration Inhalation medicine Humans Medical prescription Adrenergic beta-2 Receptor Agonists Asthma Aged Retrospective Studies Science & Technology INAPPROPRIATE Overreliance business.industry medicine.disease MAINTENANCE Budesonide/formoterol PATTERNS Short-acting β2-agonist business Demography |
| Zdroj: | Advances in Therapy |
| Popis: | Introduction Globally, individuals with asthma tend to overrely on short-acting β2-agonists (SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying inflammation. Such relief-seeking behavior has been reinforced by long-standing treatment guidelines, which until recently recommended SABA-only use for immediate symptom relief. We aimed to describe the current burden of SABA use among European individuals with asthma within the SABA use IN Asthma (SABINA) program. Methods Prescription and/or dispensing data during 2006–2017 from electronic medical records and/or national patient registries in the United Kingdom (UK), Germany, Italy, Spain, and Sweden were analyzed. Individuals aged at least 12 years old with a current asthma diagnosis and no other chronic respiratory conditions were included. Asthma treatment step and severity were based on treatment guidelines in use in each individual country. The proportion of individuals prescribed SABA was measured during a 12-month period. SABA overuse was defined as at least three SABA canisters per year. Results More than one million individuals with asthma were included across five European countries. Overall, the majority of individuals were over 45 years of age, except in Sweden (mean age 27.6 years) where individuals aged over 45 years were excluded to avoid a potential chronic obstructive pulmonary disease co-diagnosis. The study population was predominantly female (55–64%), except in the UK (46%). The prevalence of SABA overuse was 9% in Italy, 16% in Germany, 29% in Spain, 30% in Sweden, and 38% in the UK. In the UK, SABA overuse was greater in individuals with moderate-to-severe asthma versus individuals with mild asthma (58% versus 27%, respectively), while SABA overuse was similar in individuals with both mild (9–32%) and moderate-to-severe (8–31%) asthma in the other European countries. Conclusions The findings of this study from the SABINA program show that SABA overuse (at least three canisters per year) is common across Europe, despite the different healthcare and reimbursement policies of each country. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|